Ozmosi | HemaMax Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

HemaMax

Alternative Names: HemaMax, NM-IL-12, rHuIL-12, nmil12, nm il 12
Clinical Status: Inactive
Latest Update: 2026-01-21
Latest Update Note: Clinical Trial Update

Product Description

HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286478/)

Mechanisms of Action: IL12 Inhibitor

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: United Arab Emirates

Approved Indications: None

Known Adverse Events: None

Company: Neumedicines
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Diffuse Large B-Cell Lymphoma|Acute Radiation Syndrome|T-Cell Cutaneous Lymphoma|Mycosis Fungoides|Sezary Syndrome|Injuries/wounds Unspecified

Phase 1: Acute Radiation Syndrome

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT01742221

NCT01742221

P1

Completed

Acute Radiation Syndrome

2012-11-01

2019-03-22

Treatments

NCT02542124

TSEBT

P2

Unknown status

T-Cell Cutaneous Lymphoma|Sezary Syndrome|Mycosis Fungoides

2019-02-01

48%

2020-11-04

NCT02544061

2015-SWI-004

P2

Completed

Injuries/wounds Unspecified

2017-10-31

2025-08-27

NCT02544724

NM-ONC-002

P2

Unknown status

Diffuse Large B-Cell Lymphoma

2017-08-01

2019-03-20

Treatments

NCT02343133

#HHSO100201100037C

P2

Completed

Acute Radiation Syndrome

2016-04-01

2019-03-20

Treatments